As of June 2025, VRTX's current EPS stands at -$3.82, according to the latest financial reports. For the year 2024, the company recorded an earnings per share (EPS) of -$2.08, which marks a drop compared to its EPS of $14.05 in 2023. VRTX reported an EPS of $2.52 for the quarterly report ending on Mar 31, 2025.
For 2024, Vertex Pharmaceuticals's EPS was -$2.08, a drop of 114.8% from $14.05 in 2023. For the fiscal quarter that ended on Mar 31, 2025, the per-share earnings was $2.52, showing a 40.8% decrease from the same quarter last year. For the twelve months ending March 2025, the EPS is -$3.82. For the year 2023, the yearly earnings per share was $14.05, marking an increase of 8.3% from 2022.
During the last 12 months, Vertex Pharmaceuticals has seen an EPS growth of -40.8% (YoY, quarterly).
Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
---|---|---|---|---|
MRK Merck & Co Inc | 11.45 | 4,728.6% | 9.4% | 12% |
JNJ Johnson & Johnson | 17.06 | -57.9% | -9.7% | 0.4% |
BMY Bristol Myers Squibb Co | 18.05 | -213.7% | N/A | N/A |
GILD Gilead Sciences Inc | 23.5 | -91.6% | -57.5% | -38.3% |
ABBV AbbVie Inc | 80.48 | -12.1% | -28.2% | -14.7% |
ENTA Enanta Pharmaceuticals Inc | N/A | 14.1% | N/A | N/A |
VRTX Vertex Pharmaceuticals Inc | N/A | -114.8% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.